However, on the same day, Wells Fargo maintained a Hold rating on Biogen (NASDAQ: BIIB). The company has a one-year high of $238.00 and a one-year low of $128.51. Currently, Biogen has an average ...

However, today, Wells Fargo maintained a Hold rating on Biogen (NASDAQ: BIIB). The company has a one-year high of $238.00 and a one-year low of $128.51. Currently, Biogen has an average volume of ...

Biogen is continuing to thin its pipeline ... efforts on a smaller set of clinical-stage programs that we believe are high conviction and well positioned to deliver a regular cadence of pivotal ...

NASDAQ BIIB opened at $138.45 on Friday. Biogen has a fifty-two week low of $128.51 and a fifty-two week high of $238.00. The firm’s fifty day moving average price is $147.73 and its two-hundred ...

The High Court of Justice, Business and Property Courts of England ... has delivered a significant ruling in the case involving Sandoz AG and others against Biogen MA Inc. The judgment, handed down on ...

Biogen (NASDAQ:BIIB) shares traded flat in the premarket on Wednesday after the Alzheimer’s drug developer reported better-than-expected Q4 2024 financials while its full-year outlook ...

“If we could do more HI-Bios, that’s probably a nice sweet spot for us,” Viehbacher said. In the arena of external deals, Biogen has secured an R&D investment in its lupus portfolio from ...

Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing ...

Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth.

American biotechnology company Biogen (BIIB) expects lower profits in 2025, impacted by a stronger dollar (DX=F, DX-Y.NYB) and competition for its multiple sclerosis (MS) drugs. Despite this ...

Biogen’s outgoing finance chief, said on the company’s call. “Although a biosimilar has not yet launched in the U.S., we continue to see competition increasing in the high efficacy class ...